Breaking News, Collaborations & Alliances

Isis Earns GSK Milestone

Advances Phase II/III study of ISIS-TTR in FAP

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Isis Pharmaceuticals, Inc. has earned a $15 million milestone payment from GSK related to advancing the Phase II/III study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).    ISIS-TTRRx is an antisense drug the companies are developing for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues. To date, Isis has generated $60 million in upfront and milestone payments for ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters